Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Pulls Motavizumab Prophylaxis BLA, But Phase II Trial Continues

This article was originally published in The Pink Sheet Daily

Executive Summary

Company takes a $445 million charge after apparently opting not to undertake an additional trial that FDA had requested following an advisory committee, but the firm is still pursuing a possible claim for treatment of respiratory syncytial virus disease.

You may also be interested in...



Epidemiology First: MedImmune Moving Ahead With Preventive Antibodies, But Needs More HAP Data

The biotech’s senior VP for infectious disease and vaccine R&D says prevention must be a part of fighting antimicrobial resistance, but moving the new approach into advanced trials first requires getting a handle on the incidence of hospital-acquired pneumonia in intensive care patients.

MedImmune/Abbott Dispute Over Motavizumab Involves $50 Mil. In Synagis Payments

MedImmune sues Abbott following its decision not to seek approval of the second-generation respiratory syncytial virus treatment outside the U.S.

MedImmune/Abbott Dispute Over Motavizumab Involves $50 Mil. In Synagis Payments

MedImmune sues Abbott following its decision not to seek approval of the second-generation respiratory syncytial virus treatment outside the U.S.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel